QUEST DIAGNOSTICS INC
NYSE: DGX·Secaucus, New Jersey·CIK 0001022079
- Price
- $262.21
- Base IV
- $206.92
Valuation snapshot
At $262.21, the price sits between our base case ($206.92) and bull case ($338.71).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $206.92
- 79% of the price · range $99.12–$338.71
- Price vs base case
- 27% above
- $262.21 against $206.92
- Base case · our researched forecast, 2026-10-28See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $99.12 to bull $338.71. Values per share.
Price against each value
- Bear case
- $99.12
- Price 165% above
- No growth
- …
- —
- Base case
- $206.92
- Price 27% above
What does Quest Diagnostics do?
Quest Diagnostics provides laboratory testing and diagnostic insights to physicians, hospitals, and patients to help identify and treat diseases and manage healthcare.
It brought in $11.8B of sales in the 12 months to Sep 2026.
Led by James E. Davis, Chairman, Chief Executive Officer and President since 2022. Quest Diagnostics - Management Team
- Industry
- Healthcare
- Based in
- Secaucus, New Jersey
- Trades on
- NYSE as DGX
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 10¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 67¢ of every dollar.
- Making what it sells67¢
- Sales, marketing and admin17¢
- Everything else it takes to operate1¢
- Interest and other costs2¢
- Tax3¢
- Left as profit10¢
Who pays Quest Diagnostics, and for what?
Quest Diagnostics runs laboratories and patient service centers that test blood, tissue and other samples. It earns most of its revenue by providing test results and related services to healthcare providers, patients, insurers and other organizations.
Its customers include physicians, hospitals, patients and consumers, health plans, government agencies, employers, pharmaceutical companies and insurers.
Diagnostic Information Services
Laboratory and pathology testing, diagnostic insights and related services.
Laboratory analyzers used for diagnostic testing.Bobjgalindo, CC BY-SA 4.0, via Wikimedia Commons Diagnostic Solutions
Risk assessment services for insurers and information technology solutions for healthcare organizations and clinicians.
Hospital reference testing
11%Testing that hospitals send to Quest when they do not perform it in their own laboratories; Quest reported about $1.2 billion of this revenue in 2025.
Collaborative Lab Solutions
7%Hospital lab support, including lab management, test menu and purchasing support, and data solutions; Quest reported about $800 million in revenue and management fees in 2025.
Advanced Diagnostics
9%Specialized tests in areas including cancer, heart and metabolic health, brain health, autoimmune conditions, women's health and genetics generated more than $1 billion in 2025 revenue.
Where its work physically happens, beyond headquarters:
- Clifton laboratory — Clifton, United States. This highly automated laboratory serves seven Northeastern states and has capacity for more than 300,000 tests per day.
- Nichols Institute — San Juan Capistrano, United States. The institute performs complex specialty testing, including next-generation sequencing, and supports Quest’s diagnostic research and development.
- Marlborough laboratory — Marlborough, United States. This major New England testing facility also houses a diagnostic research center focused on advanced technologies and specialized testing.
- LifeLabs International Reference Laboratory — Toronto, Canada. This LifeLabs reference laboratory is a principal testing site in Quest’s Canadian diagnostic network.
- Nichols Institute Chantilly — Chantilly, United States. This esoteric reference laboratory performs a broad range of specialized tests, including genetic and oncology testing.
How is the business doing?
Sales grew from $9.4B in 2020 to $11B in 2025, about 3% a year.
Running the business leaves about 15¢ of each sales dollar as operating profit, down from 21¢ in 2020.
After paying for its upkeep and new investment, it had $1.4B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company says its purpose is to work together to help create a healthier world, one life at a time.
“Working together to create a healthier world, one life at a time.”
Who is responsible for the plan?
- James E. DavisChairman, Chief Executive Officer and President
He oversees the overall strategic direction, operations, and organizational management of Quest Diagnostics. Quest Diagnostics generates revenue primarily by providing diagnostic testing and clinical laboratory services to healthcare providers, hospitals, health plans, and consumers.
- Mark E. DelaneySenior Vice President and Chief Commercial Officer
He is responsible for overseeing all commercial sales operations across physician, hospital, health system, and employer channels. Commercial sales operations drive customer acquisition and test order volumes for the company's clinical diagnostic information services.
- Murali BalakumarSenior Vice President and Chief Information and Digital Officer
He leads the company's information technology, data informatics, digital solutions, and analytics strategies. Information technology and digital infrastructure power electronic order entry, laboratory connectivity, and automated reporting of diagnostic test results.
Roles checked November 14, 2026.
What management says it is working on now:
Serve physicians and hospitals
Management is focused on meeting demand across physician and hospital channels, including through hospital partnerships, reference testing and lab support services.
Quest Diagnostics Q3 2026 earnings call transcriptExpand consumer health
Management is growing direct-to-consumer testing and partnerships, including a planned option for people to order lab tests through the Apple Health app.
Quest Diagnostics Q3 2026 earnings call transcriptImprove productivity with automation and AI
Management says automation and AI are helping improve productivity and support growth across the business.
Quest Diagnostics Q3 2026 earnings call transcriptDevelop specialized tests
The company is advancing specialized testing in areas such as cancer and neurology, and expanding access to its diagnostic services.
Quest Diagnostics 2025 Form 10-K, Item 1: BusinessModernize ordering and billing processes
Project Nova is intended to improve provider and patient experiences and streamline the company's order-to-payment processes.
Quest Diagnostics 2025 Form 10-K, Item 1: Business
- 2026 revenue, Full year 2026
- $12.065 billion to $12.105 billion
- Quest Diagnostics Q3 2026 earnings call transcript
- 2026 adjusted diluted earnings per share, Full year 2026
- $11.25 to $11.35
- Quest Diagnostics Q3 2026 earnings call transcript
- Consumer health growth, Full year 2026
- More than 30%
- Quest Diagnostics Q3 2026 earnings call transcript
- Invigorate cost savings and productivity improvements, Annual
- About 3% annually
- Quest Diagnostics 2025 Form 10-K, Item 1: Business
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 10%.
Its operating margin is wider than a year ago: 15¢ per sales dollar, against 14¢.
Since Oct 2026 the share price has risen 4%, from $252.92 to $262.21.
Coming up
Later in 2026
Apple Health app testing service
Quest said iPhone and iPad users would be able to order lab tests through Apple Health, with a full launch expected later in 2026.
Quest Diagnostics Q3 2026 earnings call transcriptLater in 2026
Expected close of hospital outreach asset acquisition
Quest said it expects to complete an acquisition of selected outreach assets from a Northeastern U.S. health system.
Quest Diagnostics Q3 2026 earnings call transcriptFall 2027
Project Nova first lab deployment
Management said it is on schedule to begin deploying Epic solutions in its first laboratory.
Quest Diagnostics Q3 2026 earnings call transcriptMarch 25, 2027
Investor Day
Quest plans to share its long-term outlook and updates on its growth plans.
Quest Diagnostics Q3 2026 earnings call transcript
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Reimbursement and payment pressure
Government programs and insurers can lower payment rates, limit coverage or require more approvals. Quest says Medicare rate changes under PAMA could reduce revenue, and it estimated an impact of about 1% of company revenue in 2027.
From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Competition and changing testing methods
The company competes with commercial and hospital laboratories, physician offices and newer providers. Testing done at home or inside hospitals could reduce demand for Quest's services.
From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Failure to bring new tests to market
If Quest cannot develop, license or successfully launch new tests and technologies, its services may become less competitive and testing volume or revenue could suffer.
From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Quality and testing errors
Errors in testing or service could affect patient care, lead to legal claims and damage the company's reputation.
From the company's own filingsWould hit how fast sales growQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Privacy, cybersecurity and technology
Quest handles sensitive patient information and relies on technology for testing, billing and service. A cyberattack, data breach or major system failure could disrupt operations, expose information and lead to legal or reputational harm.
From the company's own filingsWould hit how much it has to reinvestQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Debt and operating costs
Quest had about $5.7 billion of debt at the end of 2025. Higher borrowing or labor and supply costs could reduce financial flexibility and put pressure on profitability.
From the company's own filingsWould hit how much of each sale it keepsQuest Diagnostics 2025 Form 10-K, Item 1A: Risk Factors
Revenue per requisition fell 4.2% in the latest quarter even as requisition volume rose 14.5%.
From our researchWould hit how fast sales growQuest Q3 2026 results
Is it a good business?
From 2016 to 2025 it earned between 8% and 19% on the capital invested in it, a median of 10%. Its cost of capital in the latest valuation is 7.3%; returns were above it in every one of the 10 years.
From 2016 to 2025 it earned between 13% and 31% on its shareholders' equity, a median of 15%.
Over 10 years its operating margin ranged from 14¢ to 22¢ per sales dollar, a median of 15¢. Gross margin ran from 33¢ to 39¢.
Cost of capital 7.3%
The number of shares has held roughly steady over the past year.
It owes $4.8B more than it holds in cash, about 2.8 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $262.21. Our put its value between $99.12 and $338.71, with $206.92 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $99.12
Despite strong recent test growth, this case assumes lower payment per order and rising costs slow Quest's sales and reduce what it keeps from them.
Base case, $206.92
After a year of strong test growth, this case assumes Quest keeps adding orders at a slower pace while holding on to roughly its recent level of profit from sales.
Bull case, $338.71
Building on recent growth in test orders, this case assumes Quest keeps expanding quickly and earns more from its larger testing network.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 27%
For Quest Diagnostics to be worth today's $262.21, sales would need to grow about 10.6% a year. We assume 5.8%. Over the last 5 years, sales grew 1.4% a year.
Or, if sales grow 5.8% as we assume, the price works with a profit margin of 18.3% (we assume 15.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 10.6% a year?
Try your own numbersWe're moderately sure of this range: it scores 59 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $206.92 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.8%
- Operating margin15.0%
- Long-term growth rate2.2%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$206.92 -21.1%


